[Effects of lysophosphatidylcholine on expression of monocyte chemoattractant protein-1 in glomerular endothelial cells].
Glomerular endothelial cells(GEC) produce monocyte chemoattractant protein-1(MCP-1), which is considered to be an important factor for the recruitment of macrophages into the glomeruli. Recent reports have suggested an association between oxidized low-density lipoprotein(ox-LDL) and progression of glomerular disease. In this study, the effects of lysophosphatidylcholine(LysoPC), a modified phospholipid produced during LDL oxidation, on MCP-1 mRNA expression in cultured bovine GEC were examined. GEC from the 8th through 10th passages were used. LysoPC substantially increased expression of MCP-1 mRNA when compared to the control. These findings led us to examine the mechanism of LysoPC-induced MCP-1 expression in GEC. LysoPC-induced MCP-1 mRNA expression in GEC was suppressed by genistein and staurosporine. It was suggested that both the tyrosinekinase(TK) and proteinkinase C(PKC) pathways were involved in LysoPC-induced MCP-1 expression in GEC. MCP-1 mRNA induction by LysoPC was also attenuated by Vitamin E. This effect may be related to the beneficial effects of Vitamin E on experimental glomerular disease models. In conclusion, LysoPC increased MCP-1 expression in GEC. This phenomenon is believed to be mediated by both the TK and PKC signaling pathways, in contrast with other vascular endothelial cells. Vitamin E also attenuated LysoPC-induced MCP-1 expression in GEC.
Mizobata
Rie
R
Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D002417:Cattle; D002478:Cells, Cultured; D018932:Chemokine CCL2 / Q000235:genetics / Q000378:metabolism*; D004727:Endothelium / Q000166:cytology / Q000378:metabolism; D015870:Gene Expression / Q000187:drug effects*; D007678:Kidney Glomerulus / Q000166:cytology* / Q000378:metabolism*; D008077:Lipoproteins, LDL / Q000009:adverse effects; D008244:Lysophosphatidylcholines / Q000009:adverse effects* / Q000037:antagonists & inhibitors; D011493:Protein Kinase C / Q000502:physiology; D011505:Protein-Tyrosine Kinases / Q000502:physiology; D012333:RNA, Messenger / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D014810:Vitamin E / Q000494:pharmacology
D000975:Antioxidants; D018932:Chemokine CCL2; D008077:Lipoproteins, LDL; D008244:Lysophosphatidylcholines; D012333:RNA, Messenger; C099252:oxidized low density lipoprotein; D014810:Vitamin E; D011505:Protein-Tyrosine Kinases; D011493:Protein Kinase C